Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Rating of “Hold” from Brokerages

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have received an average recommendation of “Hold” from the five analysts that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $3.33.

A number of research analysts have issued reports on SYRS shares. StockNews.com began coverage on shares of Syros Pharmaceuticals in a research report on Saturday. They set a “sell” rating on the stock. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright reiterated a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th.

Insiders Place Their Bets

In related news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the sale, the director now directly owns 41,070 shares of the company’s stock, valued at $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. GSA Capital Partners LLP bought a new position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned about 0.06% of Syros Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 91.47% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Trading Up 3.1 %

NASDAQ:SYRS opened at $0.18 on Monday. The firm has a fifty day simple moving average of $0.22 and a 200 day simple moving average of $1.77. The stock has a market capitalization of $4.70 million, a PE ratio of -0.06 and a beta of 1.31. Syros Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $7.96.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the company earned ($1.35) EPS. On average, equities analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.